Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Lycia Therapeutics Stock

Lycia Therapeutics Stock

www.lyciatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $203.31MM

Lycia Therapeutics is a biotechnology company and the developer of a treatment technology, Lysosomal Targeting Chimera (LYTAC), that aims to degrade extracellular proteins with the goal of treating conditions including cancer, inflammation, and autoimmune disorders. The company has a mission to uncover use cases for the LYTAC platform using extracellular protein degradation designed to target soluble and membrane-bound proteins. Lycia Therapeutics was founded in 2019 by Dr. Carolyn Bertozzi and is headquartered in San Francisco, CA.

Buy or sell Lycia Therapeutics stockLearn more about Lycia Therapeutics IPO

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Lycia Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Lycia Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Lycia Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Lycia Therapeutics investors also invested in these private companies

Venrock
Marshall Wace
Franklin Templeton Investments
Versant Ventures
Redmile Group
Janus Henderson Investors
The Invus Group
RTW Investments
Eli Lilly
Alexandria Venture Investments
Cowen Healthcare Investments

Team

Management Team

Aetna Wun Trombley Ph.D
President & Chief Executive Officer
Steve Staben Ph.D
Chief Scientific Officer
Sofia Touami Ph.D
Chief Business Officer
Jian Cao Ph.D
Vice President of Chemistry, Manufacturing and Controls (CMC)
Winsome Chung
Vice President of Finance
Matthew Holdren Ph.D
Vice President, Head of Nonclinical Development
Darrin Lindhout Ph.D
Executive Director, Head of Biologics
Sarah McWhirter Ph.D
Vice President, Head of Biology
Larry Rozsnyai Ph.D
Vice President of Intellectual Property
Nadia Tchao MD
Executive Director, Head of Translational Medicine/Early Development

Board Members

Andrew Gottesdiener MD
Venrock
Clare Ozawa Ph.D
Versant Ventures
Ming Fang
Redmile Group
Thomas Woiwode Ph.D
Versant Ventures
Timothy Anderson
Cowen Healthcare Investments

Lycia Therapeutics stock FAQs

plusminus

Can you buy Lycia Therapeutics stock?

As Lycia Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Lycia Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy Lycia Therapeutics stock?

To invest in a private company like Lycia Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Lycia Therapeutics stock?

Yes, you may be able to sell your Lycia Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Lycia Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Lycia Therapeutics stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is Lycia Therapeutics a public company?

No, Lycia Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Lycia Therapeutics’ stock price?

Lycia Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Lycia Therapeutics’ private market stock price with Forge Data.
plusminus

What is Lycia Therapeutics’ stock ticker symbol?

Lycia Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Lycia Therapeutics in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
BillionToOne
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.25B
Med City News 05/13/2024

Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases

In a series C funding round led by Venrock Healthcare Capital Partners, Lycia Therapeutics raised $106 million.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.